ImmunoGen Gets $6.5M Milestone Fee

Xconomy Boston — 

ImmunoGen, a Waltham, MA-based developer of cancer treatments, says that it expects to collect a $6.5 million milestone from its partner, South San Francisco-based biotech giant Genentech, due to the start of dosing patients in a late-stage clinical trial for breast cancer drug T-DM1. The drug includes ImmunoGen’s cancer cell-killing agent linked to Genentech’s antibody trastuzumab, which targets the HER2 protein associated with metastatic breast cancer.

By posting a comment, you agree to our terms and conditions.

Comments are closed.